Nektar Therapeutics Revenues
Nektar Therapeutics (NKTR) reported Revenues of $38.02 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-05-10
- Nektar Therapeutics revenues for the quarter ending 2018-03-31 was $38.02M, a 53.74% increase year-over-year.
- Nektar Therapeutics revenues for the quarter ending 2017-12-31 was $95.47M, a 154.92% increase year-over-year.
- Nektar Therapeutics revenues for the quarter ending 2017-09-30 was $152.93M, a 320.87% increase year-over-year.
- Nektar Therapeutics revenues for the quarter ending 2017-06-30 was $34.59M, a 5.56% increase year-over-year.
- Nektar Therapeutics revenues for fiscal 2017 was $307.71M, a 86.00% increase from fiscal 2016.
- Nektar Therapeutics revenues for fiscal 2016 was $165.44M, a 28.32% decline from fiscal 2015.
- Nektar Therapeutics revenues for fiscal 2015 was $230.78M, a 14.99% increase from fiscal 2014.
- Nektar Therapeutics revenues for fiscal 2014 was $200.71M, a 34.77% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-03-31 | $38.02M 10-Q · filed 2018-05-10 | $133.48M derived: sum of 2 quarters · filed 2018-05-10 | $286.41M derived: sum of 3 quarters · filed 2018-05-10 | $321.00M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $95.47M 10-K · filed 2018-03-01 | $248.39M derived: sum of 2 quarters · filed 2018-03-01 | $282.98M derived: sum of 3 quarters · filed 2018-03-01 | $307.71M 10-K · filed 2018-03-01 |
| 2017-09-30 | $152.93M 10-K · filed 2018-03-01 | $187.52M derived: sum of 2 quarters · filed 2018-03-01 | $212.25M 10-Q · filed 2017-11-08 | $249.69M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | $34.59M 10-K · filed 2018-03-01 | $59.32M 10-Q · filed 2017-08-09 | $96.77M derived: sum of 3 quarters · filed 2018-05-10 | $133.10M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | $24.73M 10-Q · filed 2018-05-10 | $62.18M derived: sum of 2 quarters · filed 2018-05-10 | $98.51M derived: sum of 3 quarters · filed 2018-05-10 | $131.28M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $37.45M 10-K · filed 2018-03-01 | $73.79M derived: sum of 2 quarters · filed 2018-03-01 | $106.55M derived: sum of 3 quarters · filed 2018-03-01 | $165.44M 10-K · filed 2018-03-01 |
| 2016-09-30 | $36.34M 10-K · filed 2018-03-01 | $69.10M derived: sum of 2 quarters · filed 2018-03-01 | $127.98M 10-Q · filed 2017-11-08 | $167.36M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $32.77M 10-K · filed 2018-03-01 | $91.65M 10-Q · filed 2017-08-09 | $131.02M derived: sum of 3 quarters · filed 2018-03-01 | $190.97M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $58.88M 10-K · filed 2018-03-01 | $98.25M derived: sum of 2 quarters · filed 2018-03-01 | $158.20M derived: sum of 3 quarters · filed 2018-03-01 | $180.87M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $39.37M 10-K · filed 2017-03-01 | $99.32M derived: sum of 2 quarters · filed 2017-03-01 | $121.98M derived: sum of 3 quarters · filed 2017-03-01 | $230.78M 10-K · filed 2018-03-01 |
| 2015-09-30 | $59.95M 10-K · filed 2017-03-01 | $82.61M derived: sum of 2 quarters · filed 2017-03-01 | $191.41M 10-Q · filed 2016-11-04 | $210.97M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $22.66M 10-K · filed 2017-03-01 | $131.46M 10-Q · filed 2016-08-04 | $151.01M derived: sum of 3 quarters · filed 2017-03-01 | $283.88M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $108.80M 10-K · filed 2017-03-01 | $128.35M derived: sum of 2 quarters · filed 2017-03-01 | $261.22M derived: sum of 3 quarters · filed 2017-03-01 | $289.74M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $19.55M 10-K · filed 2016-02-29 | $152.42M derived: sum of 2 quarters · filed 2016-02-29 | $180.94M derived: sum of 3 quarters · filed 2016-02-29 | $200.71M 10-K · filed 2017-03-01 |
| 2014-09-30 | $132.87M 10-K · filed 2016-02-29 | $161.38M derived: sum of 2 quarters · filed 2016-02-29 | $181.16M 10-Q · filed 2015-11-06 | $212.30M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $28.51M 10-K · filed 2016-02-29 | $48.28M 10-Q · filed 2015-08-06 | $79.43M derived: sum of 3 quarters · filed 2016-02-29 | $140.34M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $19.77M 10-K · filed 2016-02-29 | $50.92M derived: sum of 2 quarters · filed 2016-02-29 | $111.83M derived: sum of 3 quarters · filed 2016-02-29 | $145.69M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $31.15M 10-K · filed 2015-02-26 | $92.06M derived: sum of 2 quarters · filed 2015-02-26 | $125.92M derived: sum of 3 quarters · filed 2015-02-26 | $148.92M 10-K · filed 2016-02-29 |
| 2013-09-30 | $60.91M 10-K · filed 2015-02-26 | $94.77M derived: sum of 2 quarters · filed 2015-02-26 | $117.78M 10-Q · filed 2014-11-07 | $138.92M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $33.86M 10-K · filed 2015-02-26 | $56.87M 10-Q · filed 2014-08-01 | $78.01M derived: sum of 3 quarters · filed 2015-02-26 | $96.42M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $23.00M 10-K · filed 2015-02-26 | $44.15M derived: sum of 2 quarters · filed 2015-02-26 | $62.56M derived: sum of 3 quarters · filed 2015-02-26 | $86.25M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $21.15M 10-K · filed 2014-02-27 | $39.56M derived: sum of 2 quarters · filed 2014-02-27 | $63.24M derived: sum of 3 quarters · filed 2014-02-27 | $81.19M 10-K · filed 2015-02-26 |
| 2012-09-30 | $18.41M 10-K · filed 2014-02-27 | $42.10M derived: sum of 2 quarters · filed 2014-02-27 | $60.05M 10-Q · filed 2013-11-07 | $75.83M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $23.68M 10-K · filed 2014-02-27 | $41.63M 10-Q · filed 2013-08-09 | $57.41M derived: sum of 3 quarters · filed 2014-02-27 | $84.48M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $17.95M 10-K · filed 2014-02-27 | $33.73M derived: sum of 2 quarters · filed 2014-02-27 | $60.80M derived: sum of 3 quarters · filed 2014-02-27 | $78.13M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $15.78M 10-K · filed 2013-03-01 | $42.85M derived: sum of 2 quarters · filed 2013-03-01 | $60.18M derived: sum of 3 quarters · filed 2013-03-01 | $71.48M 10-K · filed 2014-02-27 |
| 2011-09-30 | $27.07M 10-K · filed 2013-03-01 | $44.40M derived: sum of 2 quarters · filed 2013-03-01 | $55.70M 10-Q · filed 2012-11-09 | $101.01M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $17.33M 10-K · filed 2013-03-01 | $28.63M 10-Q · filed 2012-08-09 | $73.94M derived: sum of 3 quarters · filed 2013-03-01 | $111.87M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $11.30M 10-K · filed 2013-03-01 | $56.61M derived: sum of 2 quarters · filed 2013-03-01 | $94.54M derived: sum of 3 quarters · filed 2013-03-01 | $137.10M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $45.31M 10-K · filed 2012-02-29 | $83.24M derived: sum of 2 quarters · filed 2012-02-29 | $125.80M derived: sum of 3 quarters · filed 2012-02-29 | $159.04M 10-K · filed 2013-03-01 |
| 2010-09-30 | $37.92M 10-K · filed 2012-02-29 | $80.49M derived: sum of 2 quarters · filed 2012-02-29 | $113.72M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $42.56M 10-K · filed 2012-02-29 | $75.80M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $33.24M 10-K · filed 2012-02-29 | |||
| 2009-12-31 | $71.93M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |